603439 三力制药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.5533.11218.28321.60717.730
总资产报酬率 ROA (%)1.3731.5328.96612.35812.496
投入资产回报率 ROIC (%)1.6392.02412.54816.01214.491

边际利润分析
销售毛利率 (%)71.23869.96369.68973.31471.739
营业利润率 (%)8.0153.79015.21420.54018.775
息税前利润/营业总收入 (%)9.3964.40315.65420.38118.425
净利润/营业总收入 (%)6.7572.82813.05018.03515.977

收益指标分析
经营活动净收益/利润总额(%)77.150267.26399.43481.74597.100
价值变动净收益/利润总额(%)1.504-3.8610.60216.5144.925
营业外收支净额/利润总额(%)-2.5194.751-0.376-0.541-1.343

偿债能力分析
流动比率 (X)1.7141.4751.4561.7802.136
速动比率 (X)1.4061.2601.1971.5711.957
资产负债率 (%)40.21546.90150.04541.47031.839
带息债务/全部投入资本 (%)27.36531.24525.36424.91617.651
股东权益/带息债务 (%)241.637199.510267.350278.973455.599
股东权益/负债合计 (%)142.181108.22895.609121.403214.220
利息保障倍数 (X)5.95510.38731.490-413.682-182.271

营运能力分析
应收账款周转天数 (天)179.633139.432107.018100.05692.784
存货周转天数 (天)251.780191.140137.480112.95798.955